

Application No.: 10/091,567

Docket No.: NEL-006

AMENDMENTS TO THE CLAIMS

Please cancel claims 13 and 16 without prejudice or disclaimer to its underlying subject matter. Please amend claims 10-12, 14-15 and 17 as set forth below:

1-7. (canceled)

8. (previously presented) A deoxyribonucleic acid (DNA) vaccine comprising a liposome-encapsulated plasmid containing a gene encoding for hemagglutinin protein.

9. (new) The vaccine as claimed in Claim 8 deliverable to a respiratory tract using intranasal administration and/or by aerosol inhalation.

10. (currently amended) The deoxyribonucleic acid (DNA) vaccine of claim 8, Use of the vaccine of claim 8 for preventing and/or treating wherein the vaccine prevents or treats an influenza virus infection.

11. (currently amended) The deoxyribonucleic acid (DNA) vaccine of claim 8, Use of the vaccine of claim 8 for eliciting wherein the vaccine elicits long-lasting protective antiviral immune responses against influenza viruses.

12. (currently amended) A plasmid vector construct pCI-HA10 comprising a gene encoding for hemagglutinin protein and capable of expressing said hemagglutinin protein in a host, said plasmid vector construct encapsulated in a liposome formulation.

13. (canceled)

14. (currently amended) A method for constructing a plasmid pCI-HA10 comprising the following steps:

- (1) amplifying hemagglutinin gene from viral and mRNA with PCR;
- (2) inserting and ligating the hemagglutinin gene into a pCI vector;
- (3) transforming the resulting vector into competent E.coli DH5<sub>α</sub> cells;

Application No.: 10/091,567

Docket No.: NEL-006

(4) transcribing and translating of pCI-HA10; and  
(5) preparing and purifying pCI-HA10 by bulk preparation method The method of  
constructing the plasmid pCI-HA10 of claim 13, and further comprising the step of  
encapsulating the plasmid pCI-HA10 in a liposome formulation, said liposome formulation  
comprising of 7% 1,2 dioleoyl-3-dimethylammonium chloride (DODAC), 78% 1,2-dioleoyl-sn-  
glycerol-3-phospho-ethanolamine (DOPE) and 15% polyethylene glycol C8 ceramide  
(PEG<sub>2000</sub>C<sub>8</sub>CER).

C1  
Cont'd

15. (currently amended) A method for constructing a plasmid pCI-HA10 comprising  
the following steps:

(1) amplifying hemagglutinin gene from viral and mRNA with PCR;  
(2) inserting and ligating the hemagglutinin gene into a pCI vector;  
(3) transforming the resulting vector into competent E.coli DH5 $\alpha$  cells;  
(4) transcribing and translating of pCI-HA10; and  
(5) preparing and purifying pCI-HA10 by bulk preparation method The method of  
constructing the plasmid pCI-HA10 of claim 13, and further comprising the step of  
encapsulating the plasmid pCI-HA10 in a liposome formulation, comprising the following steps:  
(1) preparing 7% DODAC, 78% DOPE, and 15% PEG<sub>2000</sub>C<sub>8</sub>CER at 10mg/ml  
concentrations to form a lipid film at 50 °C for 2h under vacuum;  
(2) incubating the lipid film at 50 °C for 2h under vacuum;  
(3) reconstituting the lipid film with distilled water and 1M  $\beta$ -octylglucanopyranoside  
detergent at 20% of the total preparation volume;  
(4) adding the plasmid DNA to the lipid film at a concentration of 400  $\mu$ g DNA/ml of  
10 mg/ml;  
(5) transferring the reconstituted preparation into dialysis tubing and dialyzing in 1X  
HEPES buffer solution (150 mM NaCl, 20 mM Hepes, pH 7.4) at 23 °C for 15 h; and  
(6) removing the free, non-encapsulate DNA from encapsulated DNA on a DEAE  
Sephadex CL-6B anion exchange column.

16. (cancelled)

Application No.: 10/091,567

Docket No.: NEL-006

*CI  
Cont'd*

17. (currently amended) The method of constructing A method of delivering the  
liposome-encapsulated the plasmid pCI-HA10 of claim 16-15, further comprising the step of  
delivering the liposome-encapsulated pCI-HA10 to a respiratory tract using intranasal  
administration, and/or aerosol inhalation to eliciting protective antiviral immune responses to  
influenza viruses.

18. (previously presented) A method for preventing and/or treating influenza virus infection, comprising administering to a patient in need thereof a pharmaceutically effective amount of the vaccine of claim 8.

19. (previously presented) A method for eliciting long-lasting protective antiviral immune responses against influenza viruses, comprising administering to a patient in need thereof a pharmaceutically effective amount of the vaccine of claim 8.